Stephen F. Betz - Nov 5, 2021 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Scientific Officer
Signature
/s/ Marc Wilson, as attorney-in-fact
Stock symbol
CRNX
Transactions as of
Nov 5, 2021
Transactions value $
-$463,041
Form type
4
Date filed
11/9/2021, 04:44 PM
Previous filing
Nov 3, 2021
Next filing
Nov 17, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common stock Sale -$352K -12.6K -7.07% $27.95 166K Nov 5, 2021 Direct F1, F2
transaction CRNX Common stock Sale -$111K -3.9K -2.35% $28.42 162K Nov 8, 2021 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.
F2 The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $27.952 per share. The range of sales prices on the transaction date was $27.950 to $27.959 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
F3 The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $28.422 per share. The range of sales prices on the transaction date was $28.340 to $28.500 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.